Population
Children with immune thrombocytopenia lasting 6 months or longer, and enrolled in randomised controlled trials (RCTs) and non-randomised studies, identified by systematic review (n= 498, 6 RCTs, 5 non-randomised studies).
Intervention
Thrombopoietin receptor agonists (TPO-Ras).
Comparison
Rituximab (RTX).
Outcome
The proportion of participants achieving the primary endpoint of a platelet response above 50,000 was similar for TPO-RAs (proportion= 0.71, 95% CI: 0.63-0.78) and RTX (proportion= 0.68, 95% CI: 0.53-0.82). However, considerable variation was found between the two groups with regards to the sustainability of the response and other secondary outcomes such as need for rescue and adverse events. RTX was associated with higher rates of rescue therapy.